Neuraxis, INC current report, 09 August 2023

Full document

Neuraxis, Inc. Form 8-K Summary

Reporting date: August 9, 2023, reporting an event occurring August 8, 2023. The filing concerns Neuraxis’s initial public offering of common stock. Neuraxis is incorporated in Delaware and its common stock trades on the NYSE American under the symbol NRXS.

Material Agreement and Offering

  • Neuraxis entered into an Underwriting Agreement dated August 8, 2023, with Alexander Capital, L.P., acting as representative of the underwriters.
  • The agreement relates to the company’s initial public offering described in its January 10, 2023 prospectus and Form S-1 registration statement.
  • The filing states that the agreement’s terms are substantially the same as those previously described in the registration statement.
  • The company issued a press release on August 9, 2023 announcing the pricing of the IPO; the filing text provided does not include the offering price, number of shares, gross proceeds, net proceeds, or expected closing date.

Financial Metrics and Liquidity

This 8-K does not provide revenue, earnings, cash flow, margins, debt, liquidity balances, or other operating or financial-period metrics. It also does not provide a prior-period comparison.

Guidance, Outlook, Risks, and Unusual Items

  • No financial guidance or management outlook is provided in the filing text.
  • The principal disclosed event is the execution of the IPO underwriting agreement and related pricing announcement.
  • The filing does not describe specific contingencies, risk changes, use of proceeds, dilution, or offering expenses.
  • Item 7.01 information, including the press release, is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference except where expressly stated.

Important Facts to Verify

  1. Verify the IPO price per share, shares offered, total gross proceeds, underwriting discounts, and net proceeds in the attached underwriting agreement and pricing release.
  2. Verify the IPO closing date and whether the underwriters received any overallotment option or other securities-related rights.
  3. Review the registration statement and prospectus for the intended use of proceeds, dilution, capitalization, and risk factors.
  4. Confirm any subsequent filings reporting completion of the offering and the company’s post-offering cash position.